HumaninvsPentosan Polysulfate

Humanin is a 24-amino-acid peptide (MAPRGFSCLLLLTSEIDLPVKRRA) encoded within the 16S ribosomal RNA gene of the mitochondrial genome. Its discovery in 2001 was revolutionary — it was the first identified mitochondrial-derived peptide (MDP), challenging the long-held dogma that the mitochondrial genome only encodes 13 oxidative phosphorylation subunits, 22 tRNAs, and 2 rRNAs. Humanin, along with MOTS-C and the SHLP peptides discovered later, established mitochondria as endocrine organelles.

Humanin exerts cytoprotective effects through multiple mechanisms. Extracellularly, it binds to a trimeric receptor complex composed of CNTFR (ciliary neurotrophic factor receptor alpha), WSX-1 (IL-27 receptor alpha), and gp130 (the shared signaling subunit of the IL-6 receptor family). Activation of this complex triggers JAK/STAT3 signaling, which drives expression of anti-apoptotic genes (Bcl-2, Mcl-1) and cell survival programs. Intracellularly, humanin interacts directly with two pro-apoptotic proteins: it binds IGFBP-3, preventing IGFBP-3 from translocating to mitochondria and initiating apoptosis; and it binds BAX (Bcl-2-associated X protein), preventing BAX oligomerization and insertion into the outer mitochondrial membrane — the critical step in the intrinsic (mitochondrial) apoptosis pathway that releases cytochrome c and activates caspases.

Humanin also reduces cellular stress through multiple pathways. It decreases reactive oxygen species (ROS) production by optimizing mitochondrial electron transport chain function. It reduces endoplasmic reticulum (ER) stress by modulating the unfolded protein response (UPR). It improves insulin sensitivity through STAT3-mediated effects on hypothalamic signaling and peripheral insulin receptor substrate phosphorylation. Circulating humanin levels decline with age (approximately 40% reduction between youth and old age) and are inversely correlated with markers of age-related disease, suggesting that humanin decline contributes to the increased cellular vulnerability and apoptosis susceptibility seen in aging. Its most potent synthetic analogue, HNG (S14G-humanin), has a glycine-for-serine substitution at position 14 that increases cytoprotective potency approximately 1,000-fold.

Pentosan Polysulfate (PPS) is a semi-synthetic, sulfated polysaccharide derived from beechwood hemicellulose (xylan). Its structure consists of a xylose backbone with sulfate ester groups at positions 2 and 3, giving it a high negative charge density similar to heparin and endogenous glycosaminoglycans like heparan sulfate. This polyanionic character is central to its multiple mechanisms of action.

In joint and cartilage repair, PPS stimulates chondrocyte proteoglycan synthesis — the production of aggrecan and other proteoglycans that form the hydrated gel matrix of articular cartilage. Proteoglycans are responsible for cartilage's compressive resilience and water retention, and their loss is a hallmark of osteoarthritis. PPS also inhibits matrix metalloproteinases (MMPs), particularly MMP-3, MMP-9, and MMP-13, which are the enzymes responsible for cartilage matrix degradation in osteoarthritis. By simultaneously promoting matrix synthesis and inhibiting matrix breakdown, PPS shifts the balance toward cartilage repair. Additionally, PPS improves synovial fluid viscosity by stimulating hyaluronic acid synthesis from synoviocytes, partially restoring the lubrication and shock-absorbing properties lost in arthritic joints.

PPS has several additional pharmacological properties. It inhibits complement activation (particularly the alternative pathway), reducing inflammatory damage to joint tissues. It has fibrinolytic activity — promoting the dissolution of fibrin deposits that can form in inflamed synovial tissue and contribute to joint adhesions. It inhibits certain lipases and has lipid-clearing properties. In its FDA-approved indication (interstitial cystitis), PPS is thought to replenish the damaged glycosaminoglycan layer lining the bladder epithelium, restoring the protective barrier against urine irritants. The recent FDA warning about retinal pigmentary maculopathy with long-term oral use (affecting approximately 1 in 4 long-term users) appears to be related to accumulation of PPS metabolites in the retinal pigment epithelium, where they may disrupt lysosomal function and pigment recycling.